Trials / Completed
CompletedNCT00259402
Oxaliplatin in Esophagus Cancer (Advanced) 1st Line
Phase II Open-label Single Arm Study of Oxaliplatin Combined With Cisplatin and 5FU in Advanced Esophagus Cancer Patients
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 41 (actual)
- Sponsor
- Sanofi · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
* To determine the activity and efficacy of the schema specified as dose regimen * To determine the safety and tolerability of the oxaliplatin-cisplatin and 5FU
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Oxaliplatin + cisplatin + 5-Fluorouracil (5-FU) | OXALIPLATIN 60 mg/m2/d, CISPLATIN 55 mg/m2/d, 5-FU 600 mg/m2/d with dose range and followed by radiotherapy |
Timeline
- Start date
- 2000-02-01
- Primary completion
- 2008-10-01
- Completion
- 2008-10-01
- First posted
- 2005-11-29
- Last updated
- 2009-12-07
Locations
1 site across 1 country: Spain
Source: ClinicalTrials.gov record NCT00259402. Inclusion in this directory is not an endorsement.